JAK2 and COVID-19: Tocilizumab, a monoclonal anti-IL6 receptor antibody (53), and baracitinib, a monoclonal antibody that inhibits JAK1 and JAK2 (which are activated in response to IL6 signaling) (54, 55), have also demonstrated initial clinical efficacy in COVID-19 patients.